Juhani Saarinen
Chief Executive Officer Glykos Finland Oy
Juhani Saarinen is Chief Executive Officer of Glykos, a Finland-based biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs) for the treatment of solid tumors and hematological malignancies. Under his leadership, Glykos has advanced a proprietary ADC platform featuring hydrophilic linker technologies, optimized conjugation approaches, and novel linker-payload systems designed to improve efficacy, tolerability, and therapeutic window. The company is developing a pipeline of best-in-class ADCs, including programs targeting blood cancers and solid tumors, while collaborating with pharmaceutical partners to expand the application of its technology. Juhani brings extensive experience in biotechnology leadership, drug development, and the commercialization of innovative therapeutic platforms.
Seminars
- Overcoming the physicochemical limitations of dual payload ADCs with optimized hydrophilic linker technology
- Combining auristatins, Topo1 inhibitors and novel payload modalities while optimizing DAR and payload ratios for efficacy and tolerability
- Achieving deeper and more durable antitumor activity in treatment-resistant solid tumors and hematological malignancies
